Northwire Canada EditionSunday, July 12, 2026
Northwire
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
Management Routine +

QScreen AI Appoints Former Union Pacific Vice President as Strategic Advisor to Drive Expansion into North American Rail and Transportation Markets

QScreen AI Secures Rail Veteran as Advisor Amidst Platform Completion Push

Executive Summary

Executive Summary and Strategic Appointments

  • QScreen AI Inc. appointed José Humberto "Beto" Vargas García, former Vice President at Union Pacific, as a Strategic Advisor on April 29, 2026.
  • The appointment aims to drive commercial engagement in the North American rail sector, targeting ~130,000 federally regulated safety-sensitive workers.
  • The company announced a change of auditors from Kreston GTA LLP to Bassi & Karimjee LLP effective April 13, 2026.
  • No disagreements or unresolved issues were reported with the former auditor.
Material Impact

Evaluation of News Significance

  • The appointment of a former Union Pacific VP is strategically relevant but does not constitute a guaranteed revenue contract or major equity investment disclosure in this release.
  • The news follows the April 27 announcement regarding platform completion, suggesting incremental progress rather than a fundamental shift in business trajectory.
  • Auditor change requires scrutiny; while stated as "no disagreements," switching auditors for a micro-cap company often signals internal governance reviews or cost-cutting measures that warrant caution.
QAI · Price
Company Overview

Business Model

  • QScreen AI Inc. develops an AI-driven platform that identifies probable substance impairment using standard camera hardware.
  • The system eliminates the need for blood, breath, or urine samples by analyzing physiological signals in real time.
  • Includes 13 validated clinical instruments (e.g., CIWA-Ar, COWS) to produce NCCHC-compliant documentation.
Read the original news release →

More from QScreen AI Inc.